Introduction
Mucosal melanoma (MM) is a rare disease, accounting for approximately 1.4% of all melanomas and only 0.03% of all new cancer diagnoses[1]. Traditionally, it is associated with a poor prognosis with an overall 5-year survival rate of less than 25%[1]. Progress in treatment has been hindered by rarity and lack of evidence. Studies however of treatment of subcutaneous melanoma with immunotherapy have demonstrated a significant improvement in survival rates and have become a core part of oncological strategy. This paper will discuss revision of the evidence for the use of immunotherapy in the Head and Neck.